Tryptophan catabolism drives AhR-dependent macropinocytosis and tumorigenesis in tuberous sclerosis complex

Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by hamartomatous tumors of the brain, skin, kidney and lung (lymphangioleiomyomatosis, LAM). TSC and LAM arise from biallelic inactivation of TSC1 or TSC2 which drives metabolic reprogramming, including macropinocytic scavenging of extracellular nutrients. To determine which nutrients sustain macropinocytosis, we measured dextran uptake after repletion of individual essential amino acids. Unexpectedly, only tryptophan (Trp) stimulated uptake in TSC2-deficient cells by 2.8-fold compared to amino acid-free medium (p < 0.0001), with no effect in TSC2-expressing cells. Steady-state metabolomics revealed that Trp supplementation raised intracellular Trp by 3.5-fold and lowered kynurenine by 60%. IDO1 inhibition abolished the response, indicating that Trp catabolism rather than Trp itself is the proximal signal. Interestingly, Ido1, Tdo2 and AhR were markedly upregulated in TSC2-deficient cells, and rapamycin repressed Ido1 and Tdo2 but not AhR. AhR was constitutively nuclear in TSC2-deficient cells, and rapamycin or the AhR antagonist CH-223191 returned it to the cytoplasm. Inhibition of IDO1, (Linrodostat), TDO2 (LM10) or AhR (StemRegenin 1, CH-223191) selectively decreased macropinocytosis and proliferation of TSC2-deficient cells. AhR antagonism also depleted glutathione by 70%. In vivo, StemRegenin 1 and CH-223191 reduced tumor volume by approximately 70% and 90% (p < 0.0001), respectively. Additionally, targeting AhR in the TSC2-deficient tumors strongly decreased mTORC1 activity. Collectively, our data identify a Trp-kynurenine-AhR axis that supports macropinocytosis in TSC2-deficient cells, and suggest AhR antagonists as a novel therapeutic approach for the treatment of TSC and LAM.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.765182
Primary Topic
Tuberous Sclerosis Complex Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Tryptophan catabolism drives AhR-dependent macropinocytosis and tumorigenesis in tuberous sclerosis complex

Aidan McGrath‐Conwell, Harilaos Filippakis, Elizabeth P. Henske, Carleigh Rosenberg et al.
bioRxiv (Cold Spring Harbor Laboratory)
Tuberous Sclerosis Complex Research
preprint

Tryptophan catabolism drives AhR-dependent macropinocytosis and tumorigenesis in tuberous sclerosis complex

Aidan McGrath‐Conwell, Harilaos Filippakis, Elizabeth P. Henske, Carleigh Rosenberg, Maria Moyet, James Gray, Suzanne Jalbert-Jones, Sarah Lafleur, Windrie Cox, Vishva Patel, Eleanore Gray
preprint en

Abstract

Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by hamartomatous tumors of the brain, skin, kidney and lung (lymphangioleiomyomatosis, LAM). TSC and LAM arise from biallelic inactivation of TSC1 or TSC2 which drives metabolic reprogramming, including macropinocytic scavenging of extracellular nutrients. To determine which nutrients sustain macropinocytosis, we measured dextran uptake after repletion of individual essential amino acids. Unexpectedly, only tryptophan (Trp) stimulated uptake in TSC2-deficient cells by 2.8-fold compared to amino acid-free medium (p < 0.0001), with no effect in TSC2-expressing cells. Steady-state metabolomics revealed that Trp supplementation raised intracellular Trp by 3.5-fold and lowered kynurenine by 60%. IDO1 inhibition abolished the response, indicating that Trp catabolism rather than Trp itself is the proximal signal. Interestingly, Ido1, Tdo2 and AhR were markedly upregulated in TSC2-deficient cells, and rapamycin repressed Ido1 and Tdo2 but not AhR. AhR was constitutively nuclear in TSC2-deficient cells, and rapamycin or the AhR antagonist CH-223191 returned it to the cytoplasm. Inhibition of IDO1, (Linrodostat), TDO2 (LM10) or AhR (StemRegenin 1, CH-223191) selectively decreased macropinocytosis and proliferation of TSC2-deficient cells. AhR antagonism also depleted glutathione by 70%. In vivo, StemRegenin 1 and CH-223191 reduced tumor volume by approximately 70% and 90% (p < 0.0001), respectively. Additionally, targeting AhR in the TSC2-deficient tumors strongly decreased mTORC1 activity. Collectively, our data identify a Trp-kynurenine-AhR axis that supports macropinocytosis in TSC2-deficient cells, and suggest AhR antagonists as a novel therapeutic approach for the treatment of TSC and LAM.

bioRxiv (Cold Spring Harbor Laboratory)
University of New England (US), Massachusetts General Hospital (US), Mass General Brigham (US)
Good health and well-being
Tuberous Sclerosis Complex Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon